Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subdermal Betadine to Reduce Microbacterial Bioburden During Posterior Spinal Fusion
NCT06744907Phase 4Completed
- Sponsor
- Akron Children's Hospital
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of IVIEW-1502 in surgical site infection (SSI) (2 arms), sponsored by Akron Children's Hospital. Primary endpoint: Incidence of bacterial growth in five layers of the surgical wound at 1 year. Started Jan 2025; status: completed.
02
Drugs
IVIEW-1502
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06744907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744907.